Monograph Details
|
|
Cardiovascular System
> Hyperlipoproteinemias
|
|
LOPID |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Isobutyric acid derivative. |
| Generic Name |
|
Gemfibrozil 600mg; scored tabs. |
| Indications |
|
Type IV and V hyperlipidemias resistant to dietary management, when TG levels are >1000mg/dL and pancreatitis is likely. Reduction in risk of coronary artery disease in certain Type IIb patients with HDL-C levels <35mg/dL, when response to 1st line agents and nondrug management is inadequate. |
| Children |
|
Not recommended. |
| Adults |
|
1.2g daily in 2 divided doses 30 minutes before AM and PM meals. |
| Contraindications |
|
Hepatic or renal dysfunction. Primary biliary cirrhosis. Gallbladder disease. |
| Precautions |
|
Monitor serum lipids and liver function. Discontinue if lipid response is inadequate after 3 months, or if persistent liver abnormalities or gallstones develop. Obtain blood counts periodically during first 12 months. Investigate muscle complaints; discontinue if myositis is suspected. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Anticoagulants potentiated; reduce anticoagulant dosage and monitor prothrombin time. Rhabdomyolysis and renal failure with lovastatin. Avoid use with HMG-CoA reductase inhibitors. Hypoglycemia with repaglinide. |
| Adverse Reactions |
|
Dyspepsia, abdominal pain, acute appendicitis, atrial fibrillation, gallbladder disease, cholestatic jaundice, blurred vision, paresthesias, hypesthesia, altered taste, dizziness, somnolence, peripheral neuritis, headache, depression, impotence, decreased libido, myopathy, arthralgia, synovitis, abnormal liver function tests, blood dyscrasias, angioedema, rash. |
| How Supplied |
|
Tabs 600mg—60, 500 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
